ANNX — Annexin Pharmaceuticals AB (publ) Cashflow Statement
0.000.00%
- SEK98.12m
- SEK70.73m
Annual cashflow statement for Annexin Pharmaceuticals AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -51.2 | -40.7 | -44.2 | -50.5 | -37.4 |
| Non-Cash Items | 4.47 | 0.193 | 0.193 | 0.193 | 0.193 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.74 | -0.634 | 0.58 | 0.058 | 0.24 |
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -45 | -41.2 | -43.4 | -50.2 | -36.9 |
| Capital Expenditures | 0 | 0 | 0 | 0 | -0.129 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0 | -0.26 | 0.096 | 0 | — |
| Change in Net Investments | |||||
| Cash from Investing Activities | 0 | -0.26 | 0.096 | 0 | -0.129 |
| Financing Cash Flow Items | -10.3 | -0.047 | -2.9 | 0.095 | -1.86 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 76.4 | 23.1 | 33.6 | 45.2 | 48.1 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 31.3 | -18.4 | -9.7 | -5.08 | 11.1 |